Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1989 1
1991 1
1992 3
1994 2
1996 2
1997 1
1998 2
1999 2
2000 4
2002 2
2003 1
2004 2
2005 2
2006 1
2007 6
2008 9
2009 3
2010 2
2011 6
2012 6
2013 8
2014 14
2015 9
2016 13
2017 7
2018 39
2019 79
2020 120
2021 113
2022 139
2023 207
2024 74

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Management of Coronary Disease in Patients with Advanced Kidney Disease.
Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS; ISCHEMIA-CKD Research Group. Bangalore S, et al. N Engl J Med. 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30. N Engl J Med. 2020. PMID: 32227756 Free PMC article. Clinical Trial.
Author Response.
Ramaswamy A, Kumar R, Ish P, Gupta N. Ramaswamy A, et al. Indian J Crit Care Med. 2024 Apr;28(4):405. doi: 10.5005/jp-journals-10071-24671. Indian J Crit Care Med. 2024. PMID: 38585309 Free PMC article.
How to cite this article: Ramaswamy A, Kumar R, Ish P, Gupta N. Author Response. Indian J Crit Care Med 2024;28(4):405....
How to cite this article: Ramaswamy A, Kumar R, Ish P, Gupta N. Author Response. Indian J Crit Care Med 2024;28(4):405....
1-Methyl-1'-(4-methyl-phen-yl)-2',3',5',6',7',7a'-hexa-hydro-1'H-dispiro-[piperidine-3,2'-pyrrolizine-3',3''-indoline]-4,2''-dione.
Ramaswamy S, Sribala R, Srinivasan N, Krishnakumar RV, Kumar RR. Ramaswamy S, et al. Acta Crystallogr Sect E Struct Rep Online. 2012 Sep 1;68(Pt 9):o2772-3. doi: 10.1107/S1600536812036240. Epub 2012 Aug 25. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 22969652 Free PMC article.
The title compound, C(26)H(29)N(3)O(2), crystallizes with two mol-ecules in the asymmetric unit, having C-HO inter-actions between them and resulting in a dimer characterized by an R(2) (2)(11) motif. These dimers are linked into an ABABAB chain via N-HO, N-HN and C-HO bui …
The title compound, C(26)H(29)N(3)O(2), crystallizes with two mol-ecules in the asymmetric unit, having C-HO inter-actions between them and …
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Kornblum N, et al. J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17. J Clin Oncol. 2018. PMID: 29664714 Free PMC article. Clinical Trial.
5-(4-Fluoro-benzyl-idene)-4'-(4-fluoro-phen-yl)-1,1'-dimethyl-dispiro-[piperidine-3,3'-pyrrolidine-2',3''-indoline]-4,2''-dione.
Swamy VR, Ramaswamy S, Srinivasan N, Kumar RR, Krishnakumar RV. Swamy VR, et al. Acta Crystallogr Sect E Struct Rep Online. 2012 Oct 1;68(Pt 10):o2839-40. doi: 10.1107/S1600536812037245. Epub 2012 Sep 5. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 23125644 Free PMC article.
In both independent mol-ecules, the 4-piperidinone rings adopt a similar twisted chair conformation. In the crystal, the two independent mol-ecules form an R(2) (2)(8) dimer through a pair of N-HO hydrogen bonds; the R(2) (2)(8) dimers are connected via weak C-HO hy …
In both independent mol-ecules, the 4-piperidinone rings adopt a similar twisted chair conformation. In the crystal, the two independent mol …
Structural stability of R-state conformation of carbonmonoxyl sickle and normal hemoglobin dimer.
Powrel J, Koirala RP, Adhikari NP. Powrel J, et al. J Biomol Struct Dyn. 2023 Nov;41(19):9957-9966. doi: 10.1080/07391102.2022.2150890. Epub 2022 Dec 6. J Biomol Struct Dyn. 2023. PMID: 36473709
In this work, we have studied the binding mechanism between two chains in the dimer structure of the R-state conformation of carbonmonoxyl sickle hemoglobin and is compared with that of normal hemoglobin by using molecular dynamics simulations. ...The outcomes of such inte …
In this work, we have studied the binding mechanism between two chains in the dimer structure of the R-state conformation of carbonmo …
Newly synthesized (R)-carvone-derived 1,2,3-triazoles: structural, mechanistic, cytotoxic and molecular docking studies.
Hachim ME, Oubella A, Byadi S, Fawzi M, Laamari Y, Bahsis L, Aboulmouhajir A, Morjani H, Podlipnik Č, Auhmani A, Ait Itto MY. Hachim ME, et al. J Biomol Struct Dyn. 2022 Oct;40(16):7205-7217. doi: 10.1080/07391102.2021.1894984. Epub 2021 Mar 15. J Biomol Struct Dyn. 2022. PMID: 33719863
In the current study, natural (R)-carvone was used as starting material for the efficient synthesis of several 1,2,3-triazole derivatives. ...Molecular docking and molecular dynamics confirmed the empirical test results and confirmed the stability of the complex during inh …
In the current study, natural (R)-carvone was used as starting material for the efficient synthesis of several 1,2,3-triazole derivat …
Interaction of MnTOEtPyP4 porphyrin with DNA.
Ananyan GV, Dalyan YB, Karapetyan NH, Barkhudaryan VG, Avetisyan AA. Ananyan GV, et al. J Biomol Struct Dyn. 2023 Sep-Oct;41(15):7290-7296. doi: 10.1080/07391102.2022.2120076. Epub 2022 Sep 10. J Biomol Struct Dyn. 2023. PMID: 36093964
The results show, that porphyrins interact with DNA via one binding mode at low relative concentrations (r) and two binding modes at high values of r. The binding constant (K(b)) and stoichiometry (n) were determined from binding isotherms for both porphyrin-DNA com …
The results show, that porphyrins interact with DNA via one binding mode at low relative concentrations (r) and two binding modes at …
Structural and functional insight into a new emerging target IP(3)R in cancer.
Ismatullah H, Jabeen I, Kiani YS. Ismatullah H, et al. J Biomol Struct Dyn. 2024 Feb-Mar;42(4):2170-2196. doi: 10.1080/07391102.2023.2201332. Epub 2023 Apr 17. J Biomol Struct Dyn. 2024. PMID: 37070253 Review.
Here in this review a summarized information about the role of IP(3)R in cell proliferation and apoptosis has been discussed. Moreover, structure and gating mechanism of IP(3)R in the presence of antagonists have been provided in this review. ...However, the design, …
Here in this review a summarized information about the role of IP(3)R in cell proliferation and apoptosis has been discussed. Moreove …
594 results